Latest Information

Neutrophil-to-Lymphocyte Ratio May Be Associated With mRCC Outcomes

April 26, 2012

Two recent studies have reported on the possible utility of assessing pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor in mRCC.

Tandutinib Not Effective For mRCC

April 26, 2012

A small phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases (FLT3), has concluded that the novel agent has no clinical activity and excessive toxicity, and should not be developed further for mRCC.

Low Recurrence And Cancer Death Rates Associated With Kidney Cancer Subtype

March 31, 2012

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery.

Statins May Not Protect Against Kidney Cancer

Reuters (7/29, Pittman) reports that a new study published online July 12 in the journal Cancer suggests that statins may not be linked to either an increase in, or protection from, kidney cancer.

Previously, researchers had thought that statins might affect blood vessels that feed tumors, and thus alter cancer risk. However, the data do not support this hypothesis. Researchers noted that it is possible certain statins affect cancer risk while others do not, but they were unable to investigate this for their study. They suggested that further studies are needed to clarify any possible links between statins and cancer.

Filed Under: Uncategorized